Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse.

Next Previous
Trial Profile

Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse.

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanespimycin (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms BMS-TIME-1; TIME-1
  • Sponsors Bristol-Myers Squibb; Kosan Biosciences

Most Recent Events

  • 09 Apr 2022 This trial has been completed in Spain, according to European Clinical Trials Database record
  • 31 Mar 2022 This trial has been completed in Czechia, according to European Clinical Trials Database record.
  • 19 Mar 2010 Planned end date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top